Clinical Orthopaedics and Related Research ®

A Publication of The Association of Bone and Joint Surgeons ®

Tumor 239 articles


How Long Should We Follow Patients With Soft Tissue Sarcomas?

Chigusa Sawamura MD, MPH, Seiichi Matsumoto MD, PhD, Takashi Shimoji MD, PhD, Atsushi Okawa MD, PhD, Keisuke Ae MD, PhD

Guidelines suggest that followup for low-grade soft tissue sarcomas should be every 3 to 6 months for 2 to 3 years and then annually, and for high-grade sarcomas every 3 to 6 months for 2 to 5 years, then every 6 months for the next 2 years, and then annually. However, there is only very limited evidence to support these strategies.

Incidence and Risk Factors for Pulmonary Embolism After Primary Musculoskeletal Tumor Surgery

Koichi Ogura MD, Hideo Yasunaga MD, PhD, Hiromasa Horiguchi PhD, Kazuhiko Ohe MD, PhD, Hirotaka Kawano MD, PhD

Limited information is available regarding the incidence, risk factors, and optimal prophylaxis in orthopaedic oncology patients, although malignancy and major orthopaedic surgery are associated with an increased pulmonary embolism (PE) risk.

Radiation Therapy Is Associated With Fewer Recurrences in Mesenchymal Chondrosarcoma

Satoshi Kawaguchi MD, Israel Weiss MD, Patrick P. Lin MD, Winston W. Huh MD, Valerae O. Lewis MD

Mesenchymal chondrosarcoma (MSC) is a rare variant of chondrosarcoma. Because of the rarity of the disease, most studies only contain a small number of patients and thus the prognostic variables and role of adjuvant therapies remain controversial.

Can Certain Benign Lesions of the Proximal Femur Be Treated Without Surgery?

Seung Han Shin MD, Ingwon Yeo MD, Sung Wook Seo MD, PhD

Benign lesions in the proximal femur can cause pathologic fractures. To avoid fracture, benign tumors and tumor-like lesions in this region often are treated surgically, yet there have been few reports regarding the decision-making processes or protocols for nonsurgical treatment of these lesions.

Percutaneous Doxycycline Treatment of Aneurysmal Bone Cysts With Low Recurrence Rate: A Preliminary Report

William E. Shiels DO, Joel L. Mayerson MD

Aneurysmal bone cyst (ABC) has a recurrence rate of between 12% and 71% without en bloc resection or amputation. There is no percutaneous ABC treatment drug regimen demonstrating consistent evidence of bone healing with recurrence of < 12%. Doxycyline has properties that may make it appropriate for percutaneous treatment.

Chemotherapy Influences the Pseudocapsule Composition in Soft Tissue Sarcomas

Patrick W. O’Donnell MD, PhD, J. Carlos Manivel MD, Edward Y. Cheng MD, Denis R. Clohisy MD

Soft tissue sarcomas are a heterogeneous group of malignant tumors. Standard treatment for soft tissue sarcoma of the extremity is surgical excision and adjuvant therapy; however, the role of neoadjuvant chemotherapy is controversial.

Frozen Section versus Gross Examination for Bone Marrow Margin Assessment During Sarcoma Resection

Megan E. Anderson MD, Patricia E. Miller MS, Kelsey Nostrand BS, Sara O. Vargas MD

Complete resection is critical for local control of primary bone sarcomas. Intraoperative consultation, including frozen section of bone marrow margins, frequently is used to aid in this goal.

Malignant Lymphoma of Bone: A Review of 119 Patients

Emre Demircay MD, Francis John Hornicek MD, PhD, Henry J. Mankin MD, Henry Degroot MD

Lymphoma of bone is uncommon. As a result of this, many aspects of primary lymphoma of bone (PLB) are controversial: the definition, treatment strategies, response criteria, and prognostic factors.

Iterative Curettage is Associated with Local Control in Giant Cell Tumors Involving the Distal Tibia

Saleh A. AlSulaimani MBBS, Robert E. Turcotte FRCSC

The distal tibia is an unusual location for a giant cell tumor (GCT). Treatment choices are unclear because of their rarity, the anatomy of the ankle, and difficulties associated with reconstruction.